Dr. Reddy's faces revenue slowdown post gRevlimid boost, but new investments and partnerships offer long-term growth ...

Key pharma stocks, including Granules India and Gland Pharma, have shown substantial recovery, with the Nifty Pharma index ...

Dr. Reddy's Laboratories Ltd has generally positive cash flows and an excellent current ratio of 2.58. Additionally, the ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

The daily Elliott Wave analysis for Dr Reddy Laboratories highlights a bullish trend with current market action in an impulsive phase. Orange wave 3 is unfolding within a broader navy blue wave 1 ...

Stocks including Bajaj Finserv, IREDA, Coal India, Dr Reddy's Labs, Praj Industries, JSW Energy, SpiceJet, Ashoka Buildcon ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

Dr. Reddy's Laboratories Ltd marked a 5.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy’s Laboratories Ltd, on Thursday ...